Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Unrelated umbilical cord blood refers to hematopoietic stem and progenitor cells collected from the umbilical cord and placenta of a newborn, donated by someone who is not related to the recipient. This product is used as an alternative source of allogeneic stem cells for transplantation, particularly in patients with hematologic malignancies or genetic disorders requiring hematopoietic reconstitution. The main mechanism involves engraftment of donor-derived hematopoietic stem cells, which restore bone marrow function after myeloablation. Unrelated UCB is considered antigenically “naive,” allowing for greater HLA mismatch tolerance and reduced risk of acute graft-versus-host disease (GVHD) compared to other sources like bone marrow or peripheral blood. However, it carries risks such as delayed immune reconstitution, higher rates of infection-related mortality in the early post-transplant period, and lower cell dose per unit[2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on unrelated umbilical cord blood.